The pharmaceutical industry has encountered previously unheard-of difficulties in recent years. The average cost of pharmaceuticals in the United States has increased by 24% over the past three years as a result of safety concerns, problems with certain prescriptions, and competition from both non-generic and generic medicines. This resulted in a 4% drop in prescription expenses for those with private insurance between 2010 and 2013.Developing countries such as China, India, and Brazil confront similar challenges. One potential solution is to develop a line of therapeutically beneficial vacci